We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Xvivo Perfusion AB (XVIVO) NPV

Sell:449.50 SEK Buy:450.00 SEK Change: 4.50 SEK (1.01%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:449.50 SEK
Buy:450.00 SEK
Change: 4.50 SEK (1.01%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:449.50 SEK
Buy:450.00 SEK
Change: 4.50 SEK (1.01%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Xvivo Perfusion AB is a Sweden-based medical technology company focused on developing optimized solutions for organ, tissue and cell preservation in connection with transplantation. The Company operates in two segments: Durable goods and Non-Durable goods. The Durable goods segment comprises sale and rental income from XVIVO Perfusion System (XPS) machines. The Non-Durable goods segment implies revenue from the sale of products and services that are solutions and disposable items. The Company’s product portfolio consists of Perfadex, STEEN Solution, XPS, XPS Disposable Kit, XVIVO Lung Cannula Set, XVIVO Organ Chamber, XPS PGM Disposable Sensors and Silicone Tubing Set. The Company markets its products in Europe, Asia, Middle East, and North & South America.

Contact details

Address:
Massans gata 10
GOETEBORG
412 51
Sweden
Telephone:
+46 (31) 7882150
Website:
https://www.xvivoperfusion.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
XVIVO
ISIN:
SE0004840718
Market cap:
14.05 billion SEK
Shares in issue:
31.50 million
Sector:
Health Care Supplies
Exchange:
Stockholm Stock Exchange
Country:
Sweden
Currency:
Swedish Krona
Indices:
n/a

Key personnel

  • Christoffer Rosenblad
    Chief Executive Officer
  • Lena Hagman
    Deputy Chief Executive Officer, Chief Operating Officer
  • Kristoffer Nordstroem
    Chief Financial Officer
  • Jaya Tiwari
    Vice President - Clinical and Regulatory Affairs (US)
  • Ylva Vihoj
    Global Human Resources Director
  • Katrin Gisselfaelt
    Global Quality Assurance & Regulatory Affairs Director
  • Johan Holmstroem
    Chief Commercial Officer
  • Andreas Wallinder
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.